Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

£2.25 Million Trial for Vascular Dementia Treatment

Published: Wednesday, December 04, 2013
Last Updated: Wednesday, December 04, 2013
Bookmark and Share
Researchers aim to find out if a drug for blood pressure could be effective in treating vascular dementia in a new £2.25million clinical trial.

The trial, which is funded jointly by the Alzheimer’s Society and the British Heart Foundation, is the first ever large clinical trial for patients with subcortical vascular dementia.

Vascular dementia is caused by problems with the blood supply to the brain and affects over 150,000 nationwide and 18,000 people in Northern Ireland. Those with high blood pressure, heart conditions, high cholesterol and diabetes are especially at risk, and it can be triggered by a stroke. There are currently no available treatments for vascular dementia.

Researchers from the School of Medicine, Dentistry and Biomedical Sciences at Queen’s will recruit nearly 600 people with vascular dementia for the trial. The researchers, led by Professor Peter Passmore, hope to show that 10mg a day of the drug can significantly improve memory and cognitive health. As amlodipine is already licensed and known to be safe, the treatment – which costs the NHS just £1.07 a month – could be in use as a treatment within five to ten years.

Amlodipine belongs to a class of drugs known as calcium channel blockers, which are widely used to treat high blood pressure. This will be the largest study to specifically test the drugs in people with vascular dementia, the most common type of dementia after Alzheimer’s disease. This trial will test the drug on people with the most common form of vascular dementia, but not in those whose condition was triggered by stroke.

Amlodipine is used to treat high blood pressure, a major risk factor for vascular dementia. It is known to enter the brain and researchers think it might work by protecting brain cells from damage when blood supply to the brain is poor.   Professor Peter Passmore from the School of Medicine, Dentistry and Biomedical Sciences, and lead investigator, said:   “Vascular dementia is a very common disease and to date no major trial has been successful in developing an effective treatment for this disease.  We hope, using evidence from previous research, and by trialling the drug amlodipine we may get a step closer to improving the outcomes of patients with vascular dementia within the next decade.”

Jeremy Hughes, Chief Executive at Alzheimer’s Society said:  “It’s scandalous that despite affecting 150,000 people there are no effective treatments for vascular dementia and very few new treatments under investigation. This groundbreaking trial could be the best hope we have to get an effective treatment in use in the next decade.

“Developing new drugs from scratch can costs hundreds of millions and take up to twenty years but our flagship Drug Discovery programme aims to test existing drugs in people with dementia, fast-tracking the process and bringing new treatments to market faster and more cheaply.”

Professor Peter Weissberg, Medical Director at the British Heart Foundation said: “The 2.3 million people living with coronary heart disease in the UK are at increased risk of developing vascular dementia. Unfortunately, as yet, there are no effective treatments for this devastating condition.

“Amlodipine is a widely prescribed, blood pressure lowering treatment that has shown some promising effects in vascular dementia. The BHF and Alzheimer’s Society have joined forces to fund this definitive study. If positive, it would pave the way for an affordable treatment for vascular dementia in the near future.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Big Data Can Save Lives
The sharing of genetic information from millions of cancer patients around the world could be key to revolutionising cancer prevention and care, according to a leading cancer expert from Queen's University Belfast.
Tuesday, May 17, 2016
Bowel Cancer Breakthrough May Benefit Thousands of Patients
Researchers at Queen’s University have discovered how two genes cause bowel cancer cells to become resistant to treatments used against the disease.
Monday, July 21, 2014
Major Cystic Fibrosis Breakthrough
Combination of ivacaftor with lumicaftor improves lung function and reduces patients hospitalizations.
Thursday, June 26, 2014
Drug Testing without the Pain at Queen’s
Microneedles on a sticking-plaster-like patch may be the painless and safe way doctors will test for drugs and some infections in the future.
Wednesday, December 04, 2013
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
ReadCoor Launched to Commercialize 3D Sequencing Tech
ReadCoor will leverage the Wyss Institute’s method for simultaneously sequencing and mapping RNAs within cells and tissues to advance development of diagnostics.
Ancient Eggshell Protein Breaks Through DNA Time Barrier
Fossil proteins from a 3.8million year-old eggshell have been identifed, suggests proteins could give insight into evolutionary tree.
NCI Collaborates with Multiple Myeloma Research Foundation
NCI collaborates with MMRF to incorporate genomic and clinical data into NCI Genomic Data Commons database.
New Imaging Technique in Alzheimer’s Disease
Study confirms new imaging technique corresponds a higher degree of actual brain changes.
Anti-Inflammatory Drugs Could Strengthen Airway Immunity
Mold toxins can weaken the airways' clearing mechanisms and immunity, but PKC inhibitors showed promise as a treatment.
Regulatory RNA Essential to DNA Damage Response
Researchers discover a tumour suppressor is stabilized by an RNA molecule, which helps cells respond to DNA damage.
Insight into Eye Diseases
Scientists recreate zebrafish cell regeneration from retinal stem cells in mice.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!